315 related articles for article (PubMed ID: 26643042)
1. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
Lopetuso LR; Petito V; Scaldaferri F; Gasbarrini A
Mini Rev Med Chem; 2015; 16(3):179-85. PubMed ID: 26643042
[TBL] [Abstract][Full Text] [Related]
2. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
3. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
4. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
Ponziani FR; Scaldaferri F; Petito V; Paroni Sterbini F; Pecere S; Lopetuso LR; Palladini A; Gerardi V; Masucci L; Pompili M; Cammarota G; Sanguinetti M; Gasbarrini A
Dig Dis; 2016; 34(3):269-78. PubMed ID: 27027301
[TBL] [Abstract][Full Text] [Related]
5. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
[TBL] [Abstract][Full Text] [Related]
6. Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease.
Pandolfi F; Frosali S; Petruzziello L; Newton EE; Costamagna G
Mini Rev Med Chem; 2015; 16(3):218-21. PubMed ID: 26202195
[TBL] [Abstract][Full Text] [Related]
7. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
8. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
9. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin: An Antibiotic with Important Biologic Effects.
DuPont HL
Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice.
Yang L; Liu B; Zheng J; Huang J; Zhao Q; Liu J; Su Z; Wang M; Cui Z; Wang T; Zhang W; Li Q; Lu H
Front Cell Infect Microbiol; 2019; 9():44. PubMed ID: 30886835
[TBL] [Abstract][Full Text] [Related]
13. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
14. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
Scribano ML
Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function.
Hirota SA
Mini Rev Med Chem; 2015; 16(3):206-17. PubMed ID: 26202186
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
17. Commensal Clostridia: leading players in the maintenance of gut homeostasis.
Lopetuso LR; Scaldaferri F; Petito V; Gasbarrini A
Gut Pathog; 2013 Aug; 5(1):23. PubMed ID: 23941657
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation.
Weber D; Oefner PJ; Dettmer K; Hiergeist A; Koestler J; Gessner A; Weber M; Stämmler F; Hahn J; Wolff D; Herr W; Holler E
Bone Marrow Transplant; 2016 Aug; 51(8):1087-92. PubMed ID: 26999466
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
